Next Generation Sequencing (NGS) Market - A Global and Regional Analysis: Focus on Offering, Company, Throughput, Technology Type, Sequencing, Application, End User, and Country Analysis - Analysis and Forecast, 2023-2033

Publisher BIS Research

Published Jun 13, 2023

Length 385 Pages

SKU # BIS18012919

Description

Next Generation Sequencing (NGS) Market - A Global and Regional Analysis: Focus on Offering, Company, Throughput, Technology Type, Sequencing, Application, End User, and Country Analysis - Analysis and Forecast, 2023-2033

Global NGS Market: Industry Overview

The global NGS market was valued at $6.76 billion in 2022 and is expected to reach $28.47 billion by 2033, growing at a CAGR of 13.97% during the forecast period 2023-2033. The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, the growing prevalence of non-communicable disorders, and the advancement in the performance of NGS platforms.

Market Lifecycle Stage

The global NGS market is highly consolidated. This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing. The opportunity for growth of the global NGS market lies in the development of economical and portable technologies.

Impact of COVID-19

NGS has played a crucial role in the genomic surveillance of SARS-CoV-2, the virus responsible for COVID-19. Sequencing the viral genome has helped in tracking the spread of different variants and understanding their genetic characteristics, which has been essential for public health efforts, vaccine development, and treatment strategies. NGS has been employed in studies investigating the genetic susceptibility to COVID-19 and its severity. By sequencing the genomes of affected individuals, researchers have sought to identify genetic variations associated with the risk of infection, disease progression, and response to treatment.

However, while NGS testing shot up in the research laboratories studying the transmission of the SARS-CoV-2 virus, NGS testing in the clinical setting witnessed a significant drop. The global supply chain for NGS instruments, consumables, and reagents experienced severe disruptions due to the pandemic. Manufacturing and shipping delays impacted the availability of NGS products and tests, especially in developing regions such as the Middle East, Africa, or Rest-of-the-World.

Market Segmentation:

Segmentation 1: by Offering

Consumables
Library Preparation Kits
Sequencing Kits
Equipment
Services

The global NGS market (by offering) is expected to be dominated by the consumables segment.

Segmentation 2: by Company

Illumina, Inc.
Thermo Fisher Scientific Inc.
Pacific BioSciences of California, Inc.
Oxford Nanopore Technologies plc.
Other Companies

The global NGS market (by company) is expected to be dominated by Illumina, Inc.

Segmentation 3: by Throughput

High- and Ultra-High-Throughput
Medium-Throughput
Low-Throughput

The global NGS market (by throughput) is expected to be dominated by the high- and ultra-high throughput segment.

Segmentation 4: by Technology Type

Sequencing by Synthesis
In Torrent Semiconductor Sequencing
Single Molecule Real-Time Sequencing
Nanopore Sequencing Technology
Other Technologies

The global NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.

Segmentation 5: by Sequencing

Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing

The global NGS market (by sequencing) is expected to be dominated by the targeted sequencing segment.

Segmentation 6: by Application

Clinical Diagnostics
Oncology
Non-Oncology
Research
Oncology
Non-Oncology

The global NGS market (by application) is expected to be dominated by the research segment. Within further sub-segmentation, the market is expected to be dominated by the oncology segment.

Segmentation 7: by End User

Academic and Research Institutes
Clinical Laboratories
Pharmaceutical and Biotechnology Companies
Other End Users

The global NGS market (by end user) is expected to be dominated by the academic and research insitutes segment.

Segmentation 8: by Country

North America - U.S., Canada
Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
Asia-Pacific - Japan, India, China, South Korea, Australia, Singapore, New Zealand, and Rest-of-Asia-Pacific
Middle East - U.A.E., K.S.A., Israel, Rest-of-Middle East
Rest-of-the-World - Latin America, Rest-of-Rest-of-the-World

*Note:Each country is further segmented by offering, equipment (units), and company.

Recent Developments in the Global NGS Market

In April 2023, NGeneBio signed a business agreement with Agilent Technologies, Inc.’s Korea-based subsidiary, to expand the NGS precision diagnosis in South Korea and abroad.
In March 2023, Sophia Genetics partnered with Agilent Technologies Inc. to integrate its Sophia DDM Platform with Agilent Technologies Inc.’s research-use-only SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay kit.
In March 2023, Thermo Fisher Scientific Inc. collaborated with Pfizer to expand access to NGS-based lung and breast cancer testing in more than 30 countries.
In January 2023, Qiagen N.V. completed the acquisition of Verogen, Inc. in order to deploy next-generation biometrics for forensic and molecular testing.
In October 2022, Pacific Biosciences of California, Inc. introduced two new sequencing systems, namely, Revio and Onso.
In September 2022, Illumina, Inc. introduced the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, the NovaSeq 6000 Dx. The NovaSeq 6000 Dx is a versatile platform that provides the greatest levels of compliance while also delivering useful insights for patient care.

Demand - Drivers and Limitations

The following are the drivers for the global NGS market:

Decreasing Cost of Genome Sequencing
Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings
Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare
Advantages of NGS Technology Over Other Technologies

The market is expected to face some limitations as well due to the following challenges:

Concerns Surrounding Privacy of Patient Genomic Data
Lack of Complete Reimbursement Coverage for NGS Testing

How can this report add value to an organization?

Type: The global NGS market has been extensively segmented on the basis of various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., nearly 85% of the total developments in the global NGS market.

Competitive Strategy: The global NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the global NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.

Key Companies Profiled

BGI Group
Illumina, Inc.
Thermo Fisher Scientific Inc.
Pacific Biosciences of California, Inc.
Oxford Nanopore Technologies plc.
Agilent Technologies, Inc.
Qiagen N.V.
Pillar Biosciences
Burning Rock Biotech Limited
Singular Genomics Systems, Inc.
DANAHER CORPORATION
F. Hoffmann-La Roche Ltd
Twist Bioscience Corporation
Revvity, Inc.
Centogene N.V.
Element Biosciences
Ultima Genomics
Genes2me
LifeStrands Genomics Pte. Ltd.
Alithea Genomics
Real Seq Biosciences

*PDF email from publisher allows for 1-3 users, with permission to print*

1 Markets: 1.1 Market Outlook; 1.1.1 Product Definition; 1.1.2 Inclusion and Exclusion Criteria; 1.1.3 Key Findings; 1.2 Industry Outlook; 1.2.1 NGS: Overview; 1.2.2 Historical Trends; 1.2.3 Comparative Analysis of Various Technologies; 1.2.4 Global NGS Market: Overview; 1.2.5 Emerging NGS Technologies; 1.2.5.1 In-Situ Sequencing; 1.2.5.2 Microscopy-Based Sequencing; 1.2.5.3 Future of Ultra-High Throughput NGS; 1.2.6 Current Market Scenario; 1.2.6.1 For Researchers; 1.2.6.2 For Diagnostics; 1.2.7 COVID-19 Impact on the Global NGS Market; 1.2.8 Supply Chain Analysis; 1.2.8.1 Key Entities in Supply Chain; 1.2.9 Research Publications; 1.2.10 Primary Insights; 1.2.11 Pricing Analysis; 1.3 Business Dynamics; 1.3.1 Impact Analysis; 1.3.2 Business Drivers; 1.3.2.1 Decreasing Cost of Genome Sequencing; 1.3.2.2 Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings; 1.3.2.3 Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare; 1.3.2.4 Advantages of NGS Technology over Other Technologies; 1.3.3 Business Restraints; 1.3.3.1 Concerns Surrounding the Privacy of Patient Genomic Data; 1.3.3.2 Lack of Complete Reimbursement Coverage for NGS Testing; 1.3.4 Business Opportunities; 1.3.4.1 Evolving Regulatory Landscape for Clinical NGS; 1.3.4.2 Growing Number of Gene Mutations across Various Diseases
2 Global NGS Market (by Offering), Value, Volume, 2022-2033: 2.1 Overview; 2.2 Product; 2.2.1 Consumables; 2.2.1.1 Library Preparation Kits; 2.2.1.2 Sequencing Kits; 2.2.2 Equipment; 2.2.2.1 By Company; 2.2.2.1.1 Illumina, Inc.; 2.2.2.1.1.1 NovaSeq; 2.2.2.1.1.2 NextSeq; 2.2.2.1.1.3 MiSeq; 2.2.2.1.1.4 MiniSeq; 2.2.2.1.1.5 iSeq; 2.2.2.1.2 Thermo Fisher Scientific Inc.; 2.2.2.1.2.1 Ion GeneStudio S5; 2.2.2.1.2.2 Ion PGM; 2.2.2.1.2.3 Ion Proton; 2.2.2.1.2.4 Ion Torrent Genexus; 2.2.2.1.3 Pacific Biosciences of California, Inc.; 2.2.2.1.3.1 Sequel II/IIe; 2.2.2.1.3.2 Revio; 2.2.2.1.4 Oxford Nanopore Technologies plc.; 2.2.2.1.4.1 MinION; 2.2.2.1.4.2 GridION; 2.2.2.1.4.3 PromethION; 2.2.2.1.5 Other Companies; 2.2.2.2 By Throughput; 2.2.2.2.1 High- and Ultra-High-Throughput; 2.2.2.2.2 Medium-Throughput; 2.2.2.2.3 Low-Throughput; 2.3 Services
3 Global NGS Market (by Technology Type), Value, Volume, 2022-2033: 3.1 Overview; 3.2 Sequencing by Synthesis; 3.3 Ion Torrent Semiconductor Sequencing; 3.4 Single-Molecule Real-Time (SMRT) Sequencing; 3.5 Nanopore Sequencing Technology; 3.6 Other Technologies
4 Global NGS Market (by Sequencing), Value, Volume, 2022-2033: 4.1 Overview; 4.2 Whole Genome Sequencing; 4.3 Whole Exome Sequencing; 4.4 Targeted Sequencing
5 Global NGS Market (by Application), Value, Volume, 2022-2033: 5.1 Overview; 5.2 Clinical Diagnostics; 5.2.1 Oncology; 5.2.2 Non-Oncology; 5.2.2.1 Rare Diseases; 5.2.2.2 Infectious Diseases; 5.2.2.3 Reproductive Genetics; 5.2.2.4 Other Non-Oncological Disorders; 5.3 Research; 5.3.1 Oncology; 5.3.2 Non-Oncology; 5.3.2.1 Rare Diseases; 5.3.2.2 Infectious Diseases; 5.3.2.3 Reproductive Genetics; 5.3.2.4 Other Non-Oncological Disorders
6 Global NGS Market (by End User), Value, Volume, 2022-2033: 6.1 Overview; 6.2 Academic and Research Institutes; 6.3 Clinical Laboratories; 6.4 Pharmaceutical and Biotechnology Companies; 6.5 Other End Users
7 Global NGS Market (by Region), Value, Volume, 2022-2033: 7.1 North America NGS Market; 7.1.1 Overview; 7.1.2 Legal Requirements and Framework in North America; 7.1.3 Market Dynamics; 7.1.3.1 Impact Analysis; 7.1.4 Key Distributors; 7.1.4.1 Genome Projects; 7.1.5 Market Sizing and Forecast, by Value; 7.1.5.1 North America NGS Market (by Offering), by Value; 7.1.5.1.1 North America NGS Market (Equipment), by Value; 7.1.5.1.1.1 North America NGS Market (Equipment, by Company), by Value; 7.1.5.1.1.1.1 North America NGS Market (Equipment, by Illumina, Inc.), by Value; 7.1.5.1.1.1.2 North America NGS Market (Equipment, by Thermo Fisher Scientific Inc.), by Value; 7.1.5.1.1.1.3 North America NGS Market (Equipment, by Pacific Biosciences of California, Inc.), by Value; 7.1.5.1.1.1.4 North America NGS Market (Equipment, by Oxford Nanopore Technologies plc.), by Value; 7.1.5.1.2 North America NGS Market (Equipment), by Volume; 7.1.5.1.3 North America NGS Market (by Throughput), by Value; 7.1.5.1.4 North America NGS Market (by Throughput), by Volume; 7.1.5.2 North America NGS Market (by End User); 7.1.5.2.1 North America NGS Market (Academic and Research Institutes, by Offering); 7.1.5.2.2 North America NGS Market (Clinical Laboratories, by Offering); 7.1.5.2.3 North America NGS Market (Pharmaceutical and Biotechnology Companies, by Offering); 7.1.5.2.4 North America NGS Market (Other End Users, by Offering); 7.1.5.3 North America NGS Market (by Technology Type); 7.1.5.4 North America NGS Market (by Application); 7.1.5.4.1 North America NGS Market (Application, by Clinical Diagnostics); 7.1.5.4.2 North America NGS Market (Application, by Research); 7.1.5.5 North America NGS Market (by Country); 7.1.5.5.1 U.S.; 7.1.5.5.1.1 Market Dynamics; 7.1.5.5.1.2 Market Sizing and Forecast; 7.1.5.5.1.2.1 U.S. NGS Market (by Offering), by Value; 7.1.5.5.1.2.1.1 U.S. NGS Market (Equipment), by Value; 7.1.5.5.1.2.1.1.1 U.S. NGS Market (Equipment, by Company), by Value; 7.1.5.5.1.2.1.2 U.S. NGS Market (Equipment), by Volume; 7.1.5.5.2 Canada; 7.1.5.5.2.1 Market Dynamics; 7.1.5.5.2.2 Market Sizing and Forecast; 7.1.5.5.2.2.1 Canada NGS Market (by Offering), by Value; 7.1.5.5.2.2.1.1 Canada NGS Market (Equipment), by Value; 7.1.5.5.2.2.1.1.1 Canada NGS Market (Equipment, by Company), by Value; 7.1.5.5.2.2.1.2 Canada NGS Market (Equipment), by Volume; 7.2 Europe NGS Market; 7.2.1 Overview; 7.2.2 Legal Requirements and Framework in Europe; 7.2.3 Market Dynamics; 7.2.3.1 Impact Analysis; 7.2.4 Key Distributors; 7.2.5 Genome Projects; 7.2.6 Market Sizing and Forecast, by Value; 7.2.6.1 Europe NGS Market (by Offering), by Value; 7.2.6.1.1 Europe NGS Market (Equipment), by Value; 7.2.6.1.1.1 Europe NGS Market (Equipment, by Company), by Value; 7.2.6.1.1.1.1 Europe NGS Market (Equipment, by Illumina, Inc.), by Value; 7.2.6.1.1.1.2 Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), by Value; 7.2.6.1.1.1.3 Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), by Value; 7.2.6.1.1.1.4 Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), by Value; 7.2.6.1.2 Europe NGS Market (Equipment), by Volume; 7.2.6.1.3 Europe NGS Market (by Throughput), by Value; 7.2.6.1.4 Europe NGS Market (by Throughput), by Volume; 7.2.6.2 Europe NGS Market (by End User); 7.2.6.2.1 Europe NGS Market (Academic and Research Institutes, by Offering); 7.2.6.2.2 Europe NGS Market (Clinical Laboratories, by Offering); 7.2.6.2.3 Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering); 7.2.6.2.4 Europe NGS Market (Other End Users, by Offering); 7.2.6.3 Europe NGS Market (by Technology Type); 7.2.6.4 Europe NGS Market (by Application); 7.2.6.4.1 Europe NGS Market (Application, by Clinical Diagnostics); 7.2.6.4.2 Europe NGS Market (Application, by Research); 7.2.6.5 Europe NGS Market (by Country); 7.2.6.5.1 Germany; 7.2.6.5.1.1 Market Dynamics; 7.2.6.5.1.2 Market Sizing and Forecast, by Value; 7.2.6.5.1.2.1 Germany NGS Market (by Offering), by Value; 7.2.6.5.1.2.1.1 Germany NGS Market (Equipment), by Value; 7.2.6.5.1.2.1.1.1 Germany NGS Market (Equipment, by Company), by Value; 7.2.6.5.1.2.1.2 Germany NGS Market (Equipment), by Volume; 7.2.6.5.2 U.K.; 7.2.6.5.2.1 Market Dynamics; 7.2.6.5.2.2 Market Sizing and Forecast, by Value; 7.2.6.5.2.2.1 U.K. NGS Market (by Offering), by Value; 7.2.6.5.2.2.1.1 U.K. NGS Market (Equipment), by Value; 7.2.6.5.2.2.1.1.1 U.K. NGS Market (Equipment, by Company), by Value; 7.2.6.5.2.2.1.2 U.K. NGS Market (Equipment), by Volume; 7.2.6.5.3 France; 7.2.6.5.3.1 Market Dynamics; 7.2.6.5.3.2 Market Sizing and Forecast, by Value; 7.2.6.5.3.2.1 France NGS Market (by Offering), by Value; 7.2.6.5.3.2.1.1 France NGS Market (Equipment), by Value; 7.2.6.5.3.2.1.1.1 France NGS Market (Equipment, by Company), by Value; 7.2.6.5.3.2.1.2 France NGS Market (Equipment), by Volume; 7.2.6.5.4 Italy; 7.2.6.5.4.1 Market Dynamics; 7.2.6.5.4.2 Market Sizing and Forecast, by Value; 7.2.6.5.4.2.1 Italy NGS Market (by Offering), by Value; 7.2.6.5.4.2.1.1 Italy NGS Market (Equipment), by Value; 7.2.6.5.4.2.1.1.1 Italy NGS Market (Equipment, by Company), by Value; 7.2.6.5.4.2.1.2 Italy NGS Market (Equipment), by Volume; 7.2.6.5.5 Spain; 7.2.6.5.5.1 Market Dynamics; 7.2.6.5.5.2 Market Sizing and Forecast, by Value; 7.2.6.5.5.2.1 Spain NGS Market (by Offering), by Value; 7.2.6.5.5.2.1.1 Spain NGS Market (Equipment), by Value; 7.2.6.5.5.2.1.1.1 Spain NGS Market (Equipment, by Company), by Value; 7.2.6.5.5.2.1.2 Spain NGS Market (Equipment), by Volume; 7.2.6.5.6 Rest-of-Europe; 7.2.6.5.6.1 Market Dynamics; 7.2.6.5.6.2 Market Sizing and Forecast, by Value; 7.2.6.5.6.2.1 Rest-of-Europe NGS Market (by Offering), by Value; 7.2.6.5.6.2.1.1 Rest-of-Europe NGS Market (Equipment), by Value; 7.2.6.5.6.2.1.1.1 Rest-of-Europe NGS Market (Equipment, by Company), by Value; 7.2.6.5.6.2.1.2 Rest-of-Europe NGS Market (Equipment), by Volume; 7.3 Asia-Pacific NGS Market; 7.3.1 Overview; 7.3.2 Legal Requirements and Framework in Asia-Pacific; 7.3.3 Market Dynamics; 7.3.3.1 Impact Analysis; 7.3.4 Key Distributors; 7.3.5 Genome Projects; 7.3.6 Market Sizing and Forecast, by Value; 7.3.6.1 Asia-Pacific NGS Market (by Offering), by Value; 7.3.6.1.1 Asia-Pacific NGS Market (Equipment), by Value; 7.3.6.1.1.1 Asia-Pacific NGS Market (Equipment, by Company), by Value; 7.3.6.1.1.1.1 Asia-Pacific NGS Market (Equipment, by Illumina, Inc.), by Value; 7.3.6.1.1.1.2 Asia-Pacific NGS Market (Equipment, by Thermo Fisher Scientific Inc.), by Value; 7.3.6.1.1.1.3 Asia-Pacific NGS Market (Equipment, by Pacific Biosciences of California, Inc.), by Value; 7.3.6.1.1.1.4 Asia-Pacific NGS Market (Equipment, by Oxford Nanopore Technologies plc.), by Value; 7.3.6.1.2 Asia-Pacific NGS Market (Equipment), by Volume; 7.3.6.1.3 Asia-Pacific NGS Market (by Throughput), by Value; 7.3.6.1.4 Asia-Pacific NGS Market (by Throughput), by Volume; 7.3.6.2 Asia-Pacific NGS Market (by End User); 7.3.6.2.1 Asia-Pacific NGS Market (Academic and Research Institutes, by Offering); 7.3.6.2.2 Asia-Pacific NGS Market (Clinical Laboratories, by Offering); 7.3.6.2.3 Asia-Pacific NGS Market (Pharmaceutical and Biotechnology Companies, by Offering); 7.3.6.2.4 Asia-Pacific NGS Market (Other End Users, by Offering); 7.3.6.3 Asia-Pacific NGS Market (by Technology Type); 7.3.6.4 Asia-Pacific NGS Market (by Application); 7.3.6.4.1 Asia-Pacific NGS Market (Application, by Clinical Diagnostics); 7.3.6.4.2 Asia-Pacific NGS Market (Application, by Research); 7.3.6.5 Asia-Pacific NGS Market (by Country); 7.3.6.5.1 Japan; 7.3.6.5.1.1 Market Dynamics; 7.3.6.5.1.2 Market Sizing and Forecast, by Value; 7.3.6.5.1.2.1 Japan NGS Market (by Offering), by Value; 7.3.6.5.1.2.1.1 Japan NGS Market (Equipment), by Value; 7.3.6.5.1.2.1.1.1 Japan NGS Market (Equipment, by Company), by Value; 7.3.6.5.1.2.1.2 Japan NGS Market (Equipment), by Volume; 7.3.6.5.2 China; 7.3.6.5.2.1 Market Dynamics; 7.3.6.5.2.2 Market Sizing and Forecast; 7.3.6.5.2.2.1 China NGS Market (by Offering), by Value; 7.3.6.5.2.2.1.1 China NGS Market (Equipment), by Value; 7.3.6.5.2.2.1.2 China NGS Market (Equipment), by Volume; 7.3.6.5.3 India; 7.3.6.5.3.1 Market Dynamics; 7.3.6.5.3.2 Market Sizing and Forecast, by Value; 7.3.6.5.3.2.1 India NGS Market (by Offering), by Value; 7.3.6.5.3.2.1.1 India NGS Market (Equipment), by Value; 7.3.6.5.3.2.1.2 India NGS Market (Equipment), by Volume; 7.3.6.5.4 South Korea; 7.3.6.5.4.1 Market Dynamics; 7.3.6.5.4.2 Market Sizing and Forecast, by Value; 7.3.6.5.4.2.1 South Korea NGS Market (by Offering), by Value; 7.3.6.5.4.2.1.1 South Korea NGS Market (Equipment), by Value; 7.3.6.5.4.2.1.2 South Korea NGS Market (Equipment), by Volume; 7.3.6.5.5 Australia; 7.3.6.5.5.1 Market Dynamics; 7.3.6.5.5.2 Market Sizing and Forecast, by Value; 7.3.6.5.5.2.1 Australia NGS Market (by Offering), by Value; 7.3.6.5.5.2.1.1 Australia NGS Market (Equipment), by Value; 7.3.6.5.5.2.1.2 Australia NGS Market (Equipment), by Volume; 7.3.6.5.6 Singapore; 7.3.6.5.6.1 Market Dynamics; 7.3.6.5.6.2 Market Sizing and Forecast, by Value; 7.3.6.5.6.2.1 Singapore NGS Market (by Offering), by Value; 7.3.6.5.6.2.1.1 Singapore NGS Market (Equipment), by Value; 7.3.6.5.6.2.1.2 Singapore NGS Market (Equipment), by Volume; 7.3.6.5.7 New Zealand; 7.3.6.5.7.1 Market Dynamics; 7.3.6.5.7.2 Market Sizing and Forecast, by Value; 7.3.6.5.7.2.1 New Zealand NGS Market (by Offering), by Value; 7.3.6.5.7.2.1.1 New Zealand NGS Market (Equipment), by Value; 7.3.6.5.7.2.1.2 New Zealand NGS Market (Equipment), by Volume; 7.3.6.5.8 Rest-of-Asia-Pacific; 7.3.6.5.8.1 Market Dynamics; 7.3.6.5.8.2 Market Sizing and Forecast, by Value; 7.3.6.5.8.2.1 Rest-of-Asia-Pacific NGS Market (by Offering), by Value; 7.3.6.5.8.2.1.1 Rest-of-Asia-Pacific NGS Market (Equipment), by Value; 7.3.6.5.8.2.1.2 Rest-of-Asia-Pacific NGS Market (Equipment), by Volume; 7.4 Middle East NGS Market; 7.4.1 Overview; 7.4.2 Legal Requirements and Framework in the Middle East; 7.4.3 Market Dynamics; 7.4.3.1 Impact Analysis; 7.4.4 Key Distributors; 7.4.5 Genome Projects; 7.4.6 Market Sizing and Forecast, by Value; 7.4.6.1 Middle East NGS Market (by Offering), by Value; 7.4.6.1.1 Middle East NGS Market (Equipment), by Value; 7.4.6.1.2 Middle East NGS Market (Equipment), by Volume; 7.4.6.1.3 Middle East NGS Market (by Throughput), by Value; 7.4.6.1.4 Middle East NGS Market (by Throughput), by Volume; 7.4.6.2 Middle East NGS Market (by End User); 7.4.6.2.1 Middle East NGS Market (Academic and Research Institutes, by Offering); 7.4.6.2.2 Middle East NGS Market (Clinical Laboratories, by Offering); 7.4.6.2.3 Middle East NGS Market (Pharmaceutical and Biotechnology Companies, by Offering); 7.4.6.2.4 Middle East NGS Market (Other End Users, by Offering); 7.4.6.3 Middle East NGS Market (by Technology Type); 7.4.6.4 Middle East NGS Market (by Application); 7.4.6.4.1 Middle East NGS Market (Application, by Clinical Diagnostics); 7.4.6.4.2 Middle East NGS Market (Application, by Research); 7.4.6.5 Middle East NGS Market (by Country); 7.4.6.5.1 U.A.E.; 7.4.6.5.1.1 Market Dynamics; 7.4.6.5.1.2 Market Sizing and Forecast, by Value; 7.4.6.5.1.2.1 U.A.E. NGS Market (by Offering), by Value; 7.4.6.5.1.2.1.1 U.A.E. NGS Market (Equipment), by Value; 7.4.6.5.1.2.1.2 U.A.E. NGS Market (Equipment), by Volume; 7.4.6.5.2 K.S.A.; 7.4.6.5.2.1 Market Dynamics; 7.4.6.5.2.2 Market Sizing and Forecast, by Value; 7.4.6.5.2.2.1 K.S.A. NGS Market (by Offering), by Value; 7.4.6.5.2.2.1.1 K.S.A. NGS Market (Equipment), by Value; 7.4.6.5.2.2.1.2 K.S.A. NGS Market (Equipment), by Volume; 7.4.6.5.3 Egypt; 7.4.6.5.3.1 Market Dynamics; 7.4.6.5.3.2 Market Sizing and Forecast, by Value; 7.4.6.5.3.2.1 Egypt NGS Market (by Offering), by Value; 7.4.6.5.3.2.1.1 Egypt NGS Market (Equipment), by Value; 7.4.6.5.3.2.1.2 Egypt NGS Market (Equipment), by Volume; 7.4.6.5.4 Israel; 7.4.6.5.4.1 Market Dynamics; 7.4.6.5.4.2 Market Sizing and Forecast, by Value; 7.4.6.5.4.2.1 Israel NGS Market (by Offering), by Value; 7.4.6.5.4.2.1.1 Israel NGS Market (Equipment), by Value; 7.4.6.5.4.2.1.2 Israel NGS Market (Equipment), by Volume; 7.4.6.5.5 Rest-of-Middle East; 7.4.6.5.5.1 Market Dynamics; 7.4.6.5.5.2 Market Sizing and Forecast, by Value; 7.4.6.5.5.2.1 Rest-of-Middle East NGS Market (by Offering), by Value; 7.4.6.5.5.2.1.1 Rest-of-Middle East NGS Market (Equipment), by Value; 7.4.6.5.5.2.1.2 Rest-of-Middle East NGS Market (Equipment), by Volume; 7.5 Rest-of-the-World NGS Market; 7.5.1 Overview; 7.5.2 Legal Requirements and Framework in Rest-of-the-World; 7.5.3 Market Dynamics; 7.5.3.1 Impact Analysis; 7.5.4 Genome Projects; 7.5.5 Market Sizing and Forecast, by Value; 7.5.5.1 Rest-of-the-World NGS Market (by Offering), by Value; 7.5.5.1.1 Rest-of-the-World NGS Market (Equipment), by Value; 7.5.5.1.2 Rest-of-the-World NGS Market (Equipment), by Volume; 7.5.5.1.3 Rest-of-the-World NGS Market (by Throughput), by Value; 7.5.5.1.4 Rest-of-the-World NGS Market (by Throughput), by Volume; 7.5.5.2 Rest-of-the-World NGS Market (by End User); 7.5.5.2.1 Rest-of-the-World NGS Market (Academic and Research Institutes, by Offering); 7.5.5.2.2 Rest-of-the-World NGS Market (Clinical Laboratories, by Offering); 7.5.5.2.3 Rest-of-the-World NGS Market (Pharmaceutical and Biotechnology Companies, by Offering); 7.5.5.2.4 Rest-of-the-World NGS Market (Other End Users, by Offering); 7.5.5.3 Rest-of-the-World NGS Market (by Technology Type); 7.5.5.4 Rest-of-the-World NGS Market (by Application); 7.5.5.4.1 Rest-of-the-World NGS Market (Application, by Clinical Diagnostics); 7.5.5.4.2 Rest-of-the-World NGS Market (Application, by Research); 7.5.5.5 Rest-of-the-World NGS Market (by Region); 7.5.5.5.1 Latin America; 7.5.5.5.1.1 Market Dynamics; 7.5.5.5.1.2 Market Sizing and Forecast; 7.5.5.5.1.2.1 Latin America NGS Market (by Offering); 7.5.5.5.1.2.1.1 Latin America NGS Market (Equipment); 7.5.5.5.1.2.1.2 Latin America NGS Market (Equipment); 7.5.5.5.2 Rest-of-Rest-of-the-World; 7.5.5.5.2.1 Market Dynamics; 7.5.5.5.2.2 Market Sizing and Forecast, by Value; 7.5.5.5.2.2.1 Rest-of-Rest-of-the-World NGS Market (by Offering), by Value; 7.5.5.5.2.2.1.1 Rest-of-Rest-of-the-World NGS Market (Equipment), by Value; 7.5.5.5.2.2.1.2 Rest-of-Rest-of-the-World NGS Market (Equipment), by Volume
8 Markets - Competitive Benchmarking & Company Profiles: 8.1 Competitive Landscape; 8.1.1 Overview; 8.1.2 Corporate Strategies; 8.1.2.1 Mergers and Acquisitions; 8.1.2.2 Synergistic Activities; 8.1.2.3 Business Expansions and Funding; 8.1.3 Business Strategies; 8.1.3.1 Product Launches/Upgradations/Approvals; 8.2 Market Share Analysis; 8.3 Growth-Share Analysis for the Global NGS Market (by End User); 8.4 Growth-Share Analysis for the Global NGS Market (by Throughput); 8.5 Company Profiles; 8.5.1 BGI Group; 8.5.1.1 Company Overview; 8.5.1.2 Role of BGI Group in the Global NGS Market; 8.5.1.3 Key Developments; 8.5.1.4 Target Customers; 8.5.1.5 Analyst Perception; 8.5.2 Illumina, Inc.; 8.5.2.1 Company Overview; 8.5.2.2 Role of Illumina, Inc. in the Global NGS Market; 8.5.2.3 Recent Developments; 8.5.2.4 Financials; 8.5.2.5 Target Customers; 8.5.2.6 Analyst Perception; 8.5.3 Thermo Fisher Scientific Inc.; 8.5.3.1 Company Overview; 8.5.3.2 Role of Thermo Fisher Scientific Inc. in the Global NGS Market; 8.5.3.3 Financials; 8.5.3.4 Recent Developments; 8.5.3.5 Target Customers; 8.5.3.6 Analyst Perception; 8.5.4 Pacific Biosciences of California, Inc.; 8.5.4.1 Company Overview; 8.5.4.2 Role of Pacific Biosciences of California, Inc. in the Global NGS Market; 8.5.4.3 Recent Developments; 8.5.4.4 Financials; 8.5.4.5 Target Customers; 8.5.4.6 Analyst Perception; 8.5.5 Oxford Nanopore Technologies plc.; 8.5.5.1 Company Overview; 8.5.5.2 Role of Oxford Nanopore Technologies plc. in the Global NGS Market; 8.5.5.3 Recent Developments; 8.5.5.4 Financials; 8.5.5.5 Target Customers; 8.5.5.6 Analyst Perception; 8.5.6 Agilent Technologies, Inc.; 8.5.6.1 Company Overview; 8.5.6.2 Role of Agilent Technologies, Inc. in the Global NGS Market; 8.5.6.3 Financials; 8.5.6.4 Recent Developments; 8.5.6.5 Target Customers; 8.5.6.6 Analyst’s Perspective; 8.5.7 Qiagen N.V.; 8.5.7.1 Company Overview; 8.5.7.2 Role of Qiagen N.V. in the Global NGS Market; 8.5.7.3 Financials; 8.5.7.4 Recent Developments; 8.5.7.5 Target Customers; 8.5.7.6 Analyst’s Perspective; 8.5.8 Pillar Biosciences; 8.5.8.1 Company Overview; 8.5.8.2 Role of Pillar Biosciences in the Global NGS Market; 8.5.8.3 Recent Developments; 8.5.8.4 Analyst’s Perspective; 8.5.9 Burning Rock Biotech Limited; 8.5.9.1 Company Overview; 8.5.9.2 Role of Burning Rock Biotech Limited in the Global NGS Market; 8.5.9.3 Financials; 8.5.9.4 Recent Developments; 8.5.9.5 Target Customers; 8.5.9.6 Analyst’s Perspective; 8.5.10 Singular Genomics Systems, Inc.; 8.5.10.1 Company Overview; 8.5.10.2 Role of Singular Genomics Systems, Inc. in the Global NGS Market; 8.5.10.3 Financials; 8.5.10.4 Recent Developments; 8.5.10.5 Target Customers; 8.5.10.6 Analyst’s Perspective; 8.5.11 DANAHER CORPORATION; 8.5.11.1 Company Overview; 8.5.11.2 Role of DANAHER CORPORATION in the Global NGS Market; 8.5.11.3 Financials; 8.5.11.4 Recent Developments; 8.5.11.5 Target Customers; 8.5.11.6 Analyst’s Perspective; 8.5.12 F. Hoffmann-La Roche Ltd; 8.5.12.1 Company Overview; 8.5.12.2 Role of F. Hoffmann-La Roche Ltd in the Global NGS Market; 8.5.12.3 Financials; 8.5.12.4 Recent Developments; 8.5.12.5 Target Customers; 8.5.12.6 Analyst’s Perspective; 8.5.13 Twist Bioscience Corporation; 8.5.13.1 Company Overview; 8.5.13.2 Role of Twist Bioscience Corporation in the Global NGS Market; 8.5.13.3 Financials; 8.5.13.4 Recent Developments; 8.5.13.5 Target Customers; 8.5.13.6 Analyst’s Perspective; 8.5.14 Revvity, Inc.; 8.5.14.1 Company Overview; 8.5.14.2 Role of Revvity, Inc. in the Global NGS Market; 8.5.14.3 Financials; 8.5.14.4 Recent Developments; 8.5.14.5 Target Customers; 8.5.14.6 Analyst’s Perspective; 8.5.15 Centogene N.V.; 8.5.15.1 Company Overview; 8.5.15.2 Role of Centogene N.V. in the Global NGS Market; 8.5.15.3 Financials; 8.5.15.4 Recent Developments; 8.5.15.5 Target Customers; 8.5.15.6 Analyst’s Perspective; 8.6 Emerging Company Snapshots; 8.6.1 Element Biosciences; 8.6.1.1 Company Overview; 8.6.1.2 Role of Element Biosciences in the Global NGS Market; 8.6.1.3 Recent Developments; 8.6.2 Ultima Genomics; 8.6.2.1 Company Overview; 8.6.2.2 Role of Ultima Genomics in the Global NGS Market; 8.6.2.3 Recent Developments; 8.6.3 Genes2me; 8.6.3.1 Company Overview; 8.6.3.2 Role of Genes2me in the Global NGS Market; 8.6.3.3 Recent Developments; 8.6.4 LifeStrands Genomics Pte. Ltd.; 8.6.4.1 Company Overview; 8.6.4.2 Role of LifeStrands Genomics Pte. Ltd. in the Global NGS Market; 8.6.4.3 Recent Developments; 8.6.5 Alithea Genomics; 8.6.5.1 Company Overview; 8.6.5.2 Role of Alithea Genomics in the Global NGS Market; 8.6.5.3 Recent Developments; 8.6.6 Real Seq Biosciences; 8.6.6.1 Company Overview; 8.6.6.2 Role of Real Seq Biosciences in the Global NGS Market
List of Figures: Figure 1: Global NGS Market, Impact Analysis; Figure 2: Global NGS Market (by Region), $Billion, 2022 and 2033; Figure 3: Global NGS Market Segmentation; Figure 4: Global NGS Market Research Methodology; Figure 5: Primary Research Methodology; Figure 6: Bottom-Up Approach (Segment-Wise Analysis); Figure 7: Top-Down Approach (Segment-Wise Analysis); Figure 8: Global NGS Market, NGS Workflow; Figure 9: Global NGS Market, NGS Applications; Figure 10: Key Milestones in the Development of Modern-Day NGS Technologies; Figure 11: Global NGS Market, $Billion, 2022-2033; Figure 12: Workflow of In-Situ Sequencing; Figure 13: Workflow of Microscopy-Based Sequencing; Figure 14: Challenges Associated with Multiplex Sequencing and their Solutions; Figure 15: Key Milestones of the Cancer Genome Atlas Program (TCGA); Figure 16: Key Areas of NGS Application in SARS-CoV-2 Virus Research; Figure 17: Global NGS Market, Supply Chain Analysis; Figure 18: List of Common Raw Materials and Suppliers in the Global NGS Market; Figure 19: Number of Research Publications Related to NGS, 2018-2022; Figure 20: Key Primary Insights for the Global NGS Market; Figure 21: Average Price of NGS Platforms Based on Throughput; Figure 22: Global NGS Market, Impact Analysis; Figure 23: Cost of Sequencing Human Genome ($), 2001, 2006, and 2021; Figure 24: Estimated Number of New Cancer Cases, Million, 2020, 2030, and 2040; Figure 25: Key Applications of NGS in Clinical Oncology; Figure 26: Some Population-Wide Genome Sequencing Studies in Asia-Pacific; Figure 27: Global NGS Market, Share of Global Genomic Initiatives in Different Regions (in %); Figure 28: Global NGS Informatics Market, Genome Sequencing Initiatives in Europe; Figure 29: Key Features of NGS Technology; Figure 30: Comparison of qPCR vs. NGS Technology; Figure 31: Comparison of Microarray vs. NGS Technology; Figure 32: Comparison of Sanger Sequencing vs. NGS Technology; Figure 33: Key Factors Behind Poor Reimbursement of NGS in Clinical Settings; Figure 34: Evolving Regulatory Landscape for Approval of NGS-Based Tests; Figure 35: Key Requirements for Laboratory-Developed Tests (LDTs) as per the IVDR; Figure 36: Global NGS Market (by Offering), Share (%), 2022 and 2033; Figure 37: Global NGS Market (Consumables), $Billion, 2022-2033; Figure 38: Global NGS Market (Library Preparation Kits), $Billion, 2022-2033; Figure 39: Global NGS Market (Sequencing Kits), $Billion, 2022-2033; Figure 40: Global NGS Market (Equipment), $Billion, 2022-2033; Figure 41: Global NGS Market (Illumina, Inc.), $Billion, 2022-2033; Figure 42: Global NGS Market (Illumina, Inc.), Units, 2022-2033; Figure 43: Illumina, Inc. (by Equipment), Units, Share (%), 2022 and 2033; Figure 44: Global NGS Market (NovaSeq), $Billion, 2022-2033; Figure 45: Global NGS Market (NovaSeq), Units, 2022-2033; Figure 46: Global NGS Market (NextSeq), $Billion, 2022-2033; Figure 47: Global NGS Market (NextSeq), Units, 2022-2033; Figure 48: Global NGS Market (MiSeq), $Million, 2022-2033; Figure 49: Global NGS Market (MiSeq), Units, 2022-2033; Figure 50: Global NGS Market (MiniSeq), $Million, 2022-2033; Figure 51: Global NGS Market (MiniSeq), Units, 2022-2033; Figure 52: Global NGS Market (iSeq), $Million, 2022-2033; Figure 53: Global NGS Market (iSeq), Units, 2022-2033; Figure 54: Global NGS Market (Thermo Fisher Scientific Inc.), $Billion, 2022-2033; Figure 55: Global NGS Market (Thermo Fisher Scientific Inc.), Units, 2022-2033; Figure 56: Thermo Fisher Scientific Inc. (by Equipment), Units, Share (%), 2022 and 2033; Figure 57: Global NGS Market (Ion GeneStudio S5), $Million, 2022-2033; Figure 58: Global NGS Market (Ion GeneStudio S5), Units, 2022-2033; Figure 59: Global NGS Market (Ion PGM), $Million, 2022-2033; Figure 60: Global NGS Market (Ion PGM), Units, 2022-2033; Figure 61: Global NGS Market (Ion Proton), $Million, 2022-2033; Figure 62: Global NGS Market (Ion Proton), Units, 2022-2033; Figure 63: Global NGS Market (Ion Torrent Genexus), $Million, 2022-2033; Figure 64: Global NGS Market (Ion Torrent Genexus), Units, 2022-2033; Figure 65: Global NGS Market (Pacific Biosciences of California, Inc.), $Billion, 2022-2033; Figure 66: Global NGS Market (Pacific Biosciences of California, Inc.), Units, 2022-2033; Figure 67: Pacific Biosciences of California, Inc. (by Equipment), Units, Share (%), 2022 and 2033; Figure 68: Global NGS Market (Sequel II/IIe), $Million, 2022-2033; Figure 69: Global NGS Market (Sequel II/IIe), Units, 2022-2033; Figure 70: Global NGS Market (Revio), $Million, 2022-2033; Figure 71: Global NGS Market (Revio), Units, 2022-2033; Figure 72: Global NGS Market (Oxford Nanopore Technologies plc.), $Million, 2022-2033; Figure 73: Global NGS Market (MinION), $Million, 2022-2033; Figure 74: Global NGS Market (GridION), $Million, 2022-2033; Figure 75: Global NGS Market (PromethION), $Million, 2022-2033; Figure 76: Global NGS Market (Other Companies), $Million, 2022-2033; Figure 77: Features of Key High- and Ultra-High-Throughput NGS Platforms; Figure 78: Global NGS Market (High- and Ultra-High-Throughput), $Billion, 2022-2033; Figure 79: Global NGS Market (High- and Ultra-High-Throughput, by Equipment), Units, 2022-2033; Figure 80: Features of Key Medium-Throughput NGS Platforms; Figure 81: Global NGS Market (Medium-Throughput), $Billion, 2022-2033; Figure 82: Global NGS Market (Medium-Throughput, by Equipment), Units, 2022-2033; Figure 83: Features of Key Low-Throughput NGS Platforms; Figure 84: Global NGS Market (Low-Throughput), $Billion, 2022-2033; Figure 85: Global NGS Market (Low-Throughput, by Equipment), Units, 2022-2033; Figure 86: Global NGS Market (Services), $Billion, 2022-2033; Figure 87: Global NGS Market (by Technology Type); Figure 88: Global NGS Market (by Technology Type), Share (%), 2022 and 2033; Figure 89: Steps Followed in Sequencing by Synthesis; Figure 90: Global NGS Market (Sequencing by Synthesis), $Billion, 2022-2033; Figure 91: Process of Ion Torrent Semiconductor Sequencing; Figure 92: Global NGS Market (Ion Torrent Semiconductor Sequencing), $Billion, 2022-2033; Figure 93: Process of Single-Molecule Real-Time Sequencing; Figure 94: Global NGS Market (Single-Molecule Real-Time Sequencing), $Billion, 2022-2033; Figure 95: Process of Nanopore Sequencing; Figure 96: Global NGS Market (Nanopore Sequencing Technology), $Million, 2022-2033; Figure 97: Other NGS Technologies; Figure 98: Global NGS Market (Other Technologies), $Million, 2022-2033; Figure 99: Global NGS Market (by Sequencing); Figure 100: Global NGS Market (by Sequencing), Share (%), 2022 and 2033; Figure 101: Global NGS Market (Whole Genome Sequencing), $Billion, 2022-2033; Figure 102: Global NGS Market (Whole Exome Sequencing), $Billion, 2022-2033; Figure 103: Global NGS Market (Targeted Sequencing), $Billion, 2022-2033; Figure 104: Global NGS Market (by Application); Figure 105: Global NGS Market (by Application), Share (%), 2022 and 2033; Figure 106: Key Areas of NGS Application in Clinical Diagnostics; Figure 107: Global NGS Market (Clinical Diagnostics), $Billion, 2022-2033; Figure 108: Applications of NGS in Oncology; Figure 109: Global NGS Market (Clinical Diagnostics, by Oncology), $Billion, 2022-2033; Figure 110: Global NGS Market (Clinical Diagnostics, by Non-Oncology), $Billion, 2022-2033; Figure 111: Global NGS Market (Clinical Diagnostics, by Rare Diseases), $Billion, 2022-2033; Figure 112: Global NGS Market (Clinical Diagnostics, by Infectious Diseases), $Billion, 2022-2033; Figure 113: Global NGS Market (Clinical Diagnostics, by Reproductive Genetics), $Billion, 2022-2033; Figure 114: Global NGS Market (Clinical Diagnostics, by Non-Oncological Disorders), $Billion, 2022-2033; Figure 115: Key Applications of NGS in Research; Figure 116: Global NGS Market (Research), $Billion, 2022-2033; Figure 117: Global NGS Market (Research, by Oncology), $Billion, 2022-2033; Figure 118: NGS RUO Solutions for Non-Oncological Disorders; Figure 119: Global NGS Market (Research, by Rare Diseases), $Billion, 2022-2033; Figure 120: Global NGS Market (Research, by Infectious Diseases), $Billion, 2022-2033; Figure 121: Global NGS Market (Research, by Reproductive Genetics), $Billion, 2022-2033; Figure 122: Global NGS Market (Research, by Non-Oncological Disorders), $Billion, 2022-2033; Figure 123: Global NGS Market (by End User); Figure 124: Global NGS Market (by End User), Share (%), 2022 and 2033; Figure 125: Global NGS Market (Academic and Research Institutes), $Billion, 2022-2033; Figure 126: Global NGS Market (Academic and Research Institutes, by Offering), $Billion, 2022-2033; Figure 127: Global NGS Market (Clinical Laboratories), $Billion, 2022-2033; Figure 128: Global NGS Market (Clinical Laboratories, by Offering), $Billion, 2022-2033; Figure 129: Global NGS Market (Pharmaceutical and Biotechnology Companies), $Billion, 2022-2033; Figure 130: Global NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Billion, 2022-2033; Figure 131: Global NGS Market (Other End Users), $Billion, 2022-2033; Figure 132: Global NGS Market (Other End Users, by Offering), $Billion, 2022-2033; Figure 133: North America NGS Market (by Country); Figure 134: North America NGS Market, $Billion, 2022-2033; Figure 135: North America NGS Market (by Offering), $Billion, 2022-2032; Figure 136: North America NGS Market (Equipment), $Billion, 2022-2033; Figure 137: North America NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 138: North America NGS Market (Equipment, by Illumina, Inc.), $Million, 2022-2033; Figure 139: North America NGS Market (Equipment, by Thermo Fisher Scientific Inc.), $Million, 2022-2033; Figure 140: North America NGS Market (Equipment, by Pacific Biosciences of California, Inc.), $Million, 2022-2033; Figure 141: North America NGS Market (Equipment, by Oxford Nanopore Technologies plc.), $Million, 2022-2033; Figure 142: North America NGS Market (Equipment), Units, 2022-2033; Figure 143: North America NGS Market (by Throughput), $Million, 2022-2033; Figure 144: North America NGS Market (by Throughput), Units, 2022-2033; Figure 145: North America NGS Market (End User), $Billion, 2022-2033; Figure 146: North America NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033; Figure 147: North America NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033; Figure 148: North America NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-2033; Figure 149: North America NGS Market (Other End Users, by Offering), $Million, 2022-2033; Figure 150: North America NGS Market (by Technology Type), $Million, 2022-2033; Figure 151: North America NGS Market (by Application), $Billion, 2022-2033; Figure 152: North America NGS Market (Application, by Clinical Diagnostics), $Billion, 2022-2033; Figure 153: North America NGS Market (Application, by Research), $Billion, 2022-2033; Figure 154: North America NGS Market (by Country), Share (%), 2022 and 2033; Figure 155: U.S. NGS Market, $Million, 2022-2033; Figure 156: U.S. NGS Market (by Offering), $Million, 2022-2033; Figure 157: U.S. NGS Market (Equipment), $Billion, 2022-2033; Figure 158: U.S. NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 159: U.S. NGS Market (Equipment), Units, 2022-2033; Figure 160: Canada NGS Market, $Billion, 2022-2033; Figure 161: Canada NGS Market (by Offering), $Billion, 2022-2033; Figure 162: Canada NGS Market (Equipment), $Billion, 2022-2033; Figure 163: Canada NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 164: Canada NGS Market (Equipment), Units, 2022-2033; Figure 165: Europe NGS Market (by Country); Figure 166: Europe NGS Market, $Billion, 2022-2033; Figure 167: Europe NGS Market (by Offering), $Billion, 2022-2032; Figure 168: Europe NGS Market (Equipment), $Billion, 2022-2033; Figure 169: Europe NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 170: Europe NGS Market (Equipment, by Illumina, Inc.), $Million, 2022-2033; Figure 171: Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), $Million, 2022-2033; Figure 172: Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), $Million, 2022-2033; Figure 173: Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), $Million, 2022-2033; Figure 174: Europe NGS Market (Equipment), Units, 2022-2033; Figure 175: Europe NGS Market (by Throughput), $Million, 2022-2033; Figure 176: Europe NGS Market (by Throughput), Units, 2022-2033; Figure 177: Europe NGS Market (by End User), $Billion, 2022-2033; Figure 178: Europe NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033; Figure 179: Europe NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033; Figure 180: Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-20233; Figure 181: Europe NGS Market (Other End Users, by Offering), $Million, 2022-2033; Figure 182: Europe NGS Market (by Technology Type), $Million, 2022-2033; Figure 183: Europe NGS Market (by Application), $Billion, 2022-2033; Figure 184: Europe NGS Market (Application, by Clinical Diagnostics), $Billion, 2022-2033; Figure 185: Europe NGS Market (Application, by Research), $Billion, 2022-2033; Figure 186: Europe NGS Market (by Country), Share (%), 2022 and 2033; Figure 187: Germany NGS Market, $Billion, 2022-2033; Figure 188: Germany NGS Market (by Offering), $Million, 2022-2033; Figure 189: Germany NGS Market (Equipment), $Million, 2022-2033; Figure 190: Germany NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 191: Germany NGS Market (Equipment), Units, 2022-2033; Figure 192: U.K. NGS Market, $Billion, 2022-2033; Figure 193: U.K. NGS Market (by Offering), $Million, 2022-2033; Figure 194: U.K. NGS Market (Equipment), $Million, 2022-2033; Figure 195: U.K. NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 196: U.K. NGS Market (Equipment), Units, 2022-2033; Figure 197: France NGS Market, $Billion, 2022-2033; Figure 198: France NGS Market (by Offering), $Million, 2022-2033; Figure 199: France NGS Market (Equipment), $Million, 2022-2033; Figure 200: France NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 201: France NGS Market (Equipment), Units, 2022-2033; Figure 202: Italy NGS Market, $Billion, 2022-2033; Figure 203: Italy NGS Market (by Offering), $Million, 2022-2033; Figure 204: Italy NGS Market (Equipment), $Million, 2022-2033; Figure 205: Italy NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 206: Italy NGS Market (Equipment), Units, 2022-2033; Figure 207: Spain NGS Market, $Billion, 2022-2033; Figure 208: Spain NGS Market (by Offering), $Million, 2022-2033; Figure 209: Spain NGS Market (Equipment), $Million, 2022-2033; Figure 210: Spain NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 211: Spain NGS Market (Equipment), Units, 2022-2033; Figure 212: Rest-of-Europe NGS Market, $Billion, 2022-2033; Figure 213: Rest-of-Europe NGS Market (by Offering), $Million, 2022-2033; Figure 214: Rest-of-Europe NGS Market (Equipment), $Million, 2022-2033; Figure 215: Rest-of-Europe NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 216: Rest-of-Europe NGS Market (Equipment), Units, 2022-2033; Figure 217: Asia-Pacific NGS Market (by Country); Figure 218: Asia-Pacific NGS Market, $Billion, 2022-2033; Figure 219: Asia-Pacific NGS Market (by Offering), $Billion, 2022-2033; Figure 220: Asia-Pacific NGS Market (Equipment), $Billion, 2022-2033; Figure 221: Asia-Pacific NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 222: Asia-Pacific NGS Market (Equipment, by Illumina, Inc.), $Million, 2022-2033; Figure 223: Asia-Pacific NGS Market (Equipment, by Thermo Fisher Scientific Inc.), $Million, 2022-2033; Figure 224: Asia-Pacific NGS Market (Equipment, by Pacific Biosciences of California, Inc.), $Million, 2022-2033; Figure 225: Asia-Pacific NGS Market (Equipment, by Oxford Nanopore Technologies plc.), $Million, 2022-2033; Figure 226: Asia-Pacific NGS Market (Equipment), Units, 2022-2033; Figure 227: Asia-Pacific NGS Market (by Throughput), $Million, 2022-2033; Figure 228: Asia-Pacific NGS Market (by Throughput), Units, 2022-2033; Figure 229: Asia-Pacific NGS Market (by End User), $Billion, 2022-2033; Figure 230: Asia-Pacific NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033; Figure 231: Asia-Pacific NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033; Figure 232: Asia-Pacific NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-20233; Figure 233: Asia-Pacific NGS Market (Other End Users, by Offering), $Million, 2022-2033; Figure 234: Asia-Pacific NGS Market (by Technology Type), $Million, 2022-2033; Figure 235: Asia-Pacific NGS Market (by Application), $Billion, 2022-2033; Figure 236: Asia-Pacific NGS Market (Application, by Clinical Diagnostics), $Million, 2022-2033; Figure 237: Asia-Pacific NGS Market (Application, by Research), $Billion, 2022-2033; Figure 238: Asia-Pacific NGS Market (by Country), Share (%), 2022 and 2033; Figure 239: Japan NGS Market, $Billion, 2022-2033; Figure 240: Japan NGS Market (by Offering), $Million, 2022-2033; Figure 241: Japan NGS Market (Equipment), $Billion, 2022-2033; Figure 242: Japan NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 243: Japan NGS Market (Equipment), Units, 2022-2033; Figure 244: China NGS Market, $Billion, 2022-2033; Figure 245: China NGS Market (by Offering), $Billion, 2022-2033; Figure 246: China NGS Market (Equipment), $Billion, 2022-2033; Figure 247: China NGS Market (Equipment), Units, 2022-2033; Figure 248: India NGS Market, $Billion, 2022-2033; Figure 249: India NGS Market (by Offering), $Million, 2022-2033; Figure 250: India NGS Market (Equipment), $Billion, 2022-2033; Figure 251: India NGS Market (Equipment), Units, 2022-2033; Figure 252: South Korea NGS Market, $Billion, 2022-2033; Figure 253: South Korea NGS Market (by Offering), $Million, 2022-2033; Figure 254: South Korea NGS Market (Equipment), $Billion, 2022-2033; Figure 255: South Korea NGS Market (Equipment), Units, 2022-2033; Figure 256: Australia NGS Market, $Million, 2022-2033; Figure 257: Australia NGS Market (by Offering), $Million, 2022-2033; Figure 258: Australia NGS Market (Equipment), $Billion, 2022-2033; Figure 259: Australia NGS Market (Equipment), Units, 2022-2033; Figure 260: Singapore NGS Market, $Billion, 2022-2033; Figure 261: Singapore NGS Market (by Offering), $Million, 2022-2033; Figure 262: Singapore NGS Market (Equipment), $Million, 2022-2033; Figure 263: Singapore NGS Market (Equipment), Units, 2022-2033; Figure 264: New Zealand NGS Market, $Million, 2022-2033; Figure 265: New Zealand NGS Market (by Offering), $Million, 2022-2033; Figure 266: New Zealand NGS Market (Equipment), $Million, 2022-2033; Figure 267: New Zealand NGS Market (Equipment), Units, 2022-2033; Figure 268: Rest-of-Asia-Pacific NGS Market, $Billion, 2022-2033; Figure 269: Rest-of-Asia-Pacific NGS Market (by Offering), $Million, 2022-2033; Figure 270: Rest-of-Asia-Pacific NGS Market (Equipment), $Million, 2022-2033; Figure 271: Rest-of-Asia-Pacific NGS Market (Equipment), Units, 2022-2033; Figure 272: Middle East NGS Market (by Country); Figure 273: Middle East NGS Market, $Billion, 2022-2033; Figure 274: Middle East NGS Market (by Offering), $Billion, 2022-2032; Figure 275: Middle East NGS Market (Equipment), $Billion, 2022-2033; Figure 276: Middle East NGS Market (Equipment), Units, 2022-2033; Figure 277: Middle East NGS Market (by Throughput), $Million, 2022-2033; Figure 278: Middle East NGS Market (by Throughput), Units, 2022-2033; Figure 279: Middle East NGS Market (by End User), $Million, 2022-2033; Figure 280: Middle East NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033; Figure 281: Middle East NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033; Figure 282: Middle East NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-2033; Figure 283: Middle East NGS Market (Other End Users, by Offering), $Million, 2022-2033; Figure 284: Middle East NGS Market (by Technology Type), $Million, 2022-2033; Figure 285: Middle East NGS Market (by Application), $Billion, 2022-2033; Figure 286: Middle East NGS Market (Application, by Clinical Diagnostics), $Million, 2022-2033; Figure 287: Middle East NGS Market (Application, by Research), $Million, 2022-2033; Figure 288: Middle East NGS Market (by Country), Share (%), 2022 and 2033; Figure 289: U.A.E. NGS Market, $Billion, 2022-2033; Figure 290: U.A.E. NGS Market (by Offering), $Million, 2022-2033; Figure 291: U.A.E. NGS Market (Equipment), $Million, 2022-2033; Figure 292: U.A.E. NGS Market (Equipment), Units, 2022-2033; Figure 293: K.S.A. NGS Market, $Billion, 2022-2033; Figure 294: K.S.A. NGS Market (by Offering), $Million, 2022-2033; Figure 295: K.S.A. NGS Market (Equipment), $Million, 2022-2033; Figure 296: K.S.A. NGS Market (Equipment), Units, 2022-2033; Figure 297: Egypt NGS Market, $Billion, 2022-2033; Figure 298: Egypt NGS Market (by Offering), $Million, 2022-2033; Figure 299: Egypt NGS Market (Equipment), $Million, 2022-2033; Figure 300: Egypt NGS Market (Equipment), Units, 2022-2033; Figure 301: Israel NGS Market, $Million, 2022-2033; Figure 302: Israel NGS Market (by Offering), $Million, 2022-2033; Figure 303: Israel NGS Market (Equipment), $Million, 2022-2033; Figure 304: Israel NGS Market (Equipment), Units, 2022-2033; Figure 305: Rest-of-Middle East NGS Market, $Billion, 2022-2033; Figure 306: Rest-of-Middle East NGS Market (by Offering), $Million, 2022-2033; Figure 307: Rest-of-Middle East NGS Market (Equipment), $Million, 2022-2033; Figure 308: Rest-of-Middle East NGS Market (Equipment), Units, 2022-2033; Figure 309: Rest-of-the-World NGS Market (by Country); Figure 310: Rest-of-the-World NGS Market, $Billion, 2023-2033; Figure 311: Rest-of-the-World NGS Market (by Offering), $Million, 2022-2032; Figure 312: Rest-of-the-World NGS Market (Equipment), $Million, 2022-2033; Figure 313: Rest-of-the-World NGS Market (Equipment), Units, 2022-2033; Figure 314: Rest-of-the-World NGS Market (by Throughput), $Million, 2022-2033; Figure 315: Rest-of-the-World NGS Market (by Throughput), Units, 2022-2033; Figure 316: Rest-of-the-World NGS Market (by End User), $Million, 2022-2033; Figure 317: Rest-of-the-World NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033; Figure 318: Rest-of-the-World NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033; Figure 319: Rest-of-the-World NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-20233; Figure 320: Rest-of-the-World NGS Market (Other End Users, by Offering), $Million, 2022-2033; Figure 321: Rest-of-the-World NGS Market (by Technology Type), $Million, 2022-2033; Figure 322: Rest-of-the-World NGS Market (by Application), $Billion, 2022-2033; Figure 323: Rest-of-the-World NGS Market (Application, by Clinical Diagnostics), $Million, 2022-2033; Figure 324: Rest-of-the-World NGS Market (Application, by Research), $Million, 2022-2033; Figure 325: Rest-of-the-World NGS Market (by Region), Share (%), 2022 and 2033; Figure 326: Latin America NGS Market, $Billion, 2022-2033; Figure 327: Latin America NGS Market (by Offering), $Million, 2022-2033; Figure 328: Latin America NGS Market (Equipment), $Million, 2022-2033; Figure 329: Latin America NGS Market (Equipment), Units, 2022-2033; Figure 330: Rest-of-Rest-of-the-World NGS Market, $Billion, 2022-2033; Figure 331: Rest-of-Rest-of-the-World NGS Market (by Offering), $Million, 2022-2033; Figure 332: Rest-of-Rest-of-the-World NGS Market (Equipment), $Million, 2022-2033; Figure 333: Rest-of-Rest-of-the-World NGS Market (Equipment), Units, 2022-2033; Figure 334: Share of Key Developments, January 2019-May 2023; Figure 335: Number of Mergers and Acquisitions (by Company), January 2019-May 2023; Figure 336: Share of Synergistic Activities (by Company), January 2019-May 2023; Figure 337: Number of Business Expansions and Funding Activities (by Company), January 2019-May 2023; Figure 338: Share of Product Launches/Upgradations/Approvals (by Company), January 2019-May 2023; Figure 339: Market Share Analysis for Global NGS Market (by Company), 2022; Figure 340: Growth-Share Analysis for the Global NGS Market (by End User), 2022; Figure 341: Growth-Share Analysis for the Global NGS Market (by Throughput), 2022; Figure 342: Share of Companies Profiled; Figure 343: BGI Group: Overall Product Portfolio; Figure 344: Illumina, Inc.: Overall Product Portfolio; Figure 345: Illumina, Inc.: Overall Financials, $Million, 2020-2022; Figure 346: Illumina, Inc.: Segment Revenues, $Million, 2020-2022; Figure 347: Illumina, Inc.: Net Revenue (by Region), $Million, 2020-2022; Figure 348: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022; Figure 349: Thermo Fisher Scientific Inc.: Overall Product Portfolio; Figure 350: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022; Figure 351: Thermo Fisher Scientific Inc.: Segment Revenues, $Million, 2020-2022; Figure 352: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2020-2022; Figure 353: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022; Figure 354: Pacific Biosciences of California, Inc.: Overall Product Portfolio; Figure 355: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2020-2022; Figure 356: Pacific Biosciences of California, Inc.: Segment Revenue, $Million, 2020-2022; Figure 357: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2020-2022; Figure 358: Oxford Nanopore Technologies plc.: Overall Product Portfolio; Figure 359: Oxford Nanopore Technologies plc.: Overall Financials, $Million, 2020-2022; Figure 360: Oxford Nanopore Technologies plc.: Segment Revenue, $Million, 2020-2022; Figure 361: Oxford Nanopore Technologies plc.: Net Revenue (by Region), $Million, 2020-2022; Figure 362: Oxford Nanopore Technologies plc.: R&D Expenditure, $Million, 2020-2022; Figure 363: Agilent Technologies, Inc.: Overall Product Portfolio; Figure 364: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022; Figure 365: Agilent Technologies, Inc.: Segment Revenue, $Million, 2020-2022; Figure 366: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022; Figure 367: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022; Figure 368: Qiagen N.V.: Overall Product Portfolio; Figure 369: Qiagen N.V.: Overall Financials, $Million, 2020-2022; Figure 370: Qiagen N.V.: Segment Revenue, $Million, 2020-2022; Figure 371: Qiagen N.V.: Net Revenue (by Region), $Million, 2020-2022; Figure 372: Qiagen N.V.: R&D Expenditure, $Million, 2020-2022; Figure 373: Pillar Biosciences: Overall Product Portfolio; Figure 374: Burning Rock Biotech Limited: Overall Product Portfolio; Figure 375: Burning Rock Biotech Limited: Overall Financials, $Million, 2020-2022; Figure 376: Burning Rock Biotech Limited: Segment Revenue, $Million, 2020-2022; Figure 377: Burning Rock Biotech Limited: Net Revenue (by Region), $Million, 2020-2022; Figure 378: Burning Rock Biotech Limited: R&D Expenditure, $Million, 2020-2022; Figure 379: Singular Genomics Systems, Inc.: Overall Product Portfolio; Figure 380: Singular Genomics Systems, Inc.: Overall Financials, $Million, 2021 and 2022; Figure 381: Singular Genomics Systems, Inc.: R&D Expenditure, $Million, 2021-2022; Figure 382: DANAHER CORPORATION: Overall Product Portfolio; Figure 383: DANAHER CORPORATION: Overall Financials, $Million, 2020-2022; Figure 384: DANAHER CORPORATION: Segment Revenue, $Million, 2020-2022; Figure 385: DANAHER CORPORATION: Net Revenue (by Region), $Million, 2020-2022; Figure 386: DANAHER CORPORATION: R&D Expenditure, $Million, 2020-2022; Figure 387: F. Hoffmann-La Roche Ltd: Overall Product Portfolio; Figure 388: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022; Figure 389: F. Hoffmann-La Roche Ltd: Segment Revenue, $Million, 2020-2022; Figure 390: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022; Figure 391: Twist Bioscience Corporation: Overall Product Portfolio; Figure 392: Twist Bioscience Corporation: Overall Financials, $Million, 2020-2022; Figure 393: Twist Bioscience Corporation: Segment Revenue, $Million, 2020-2022; Figure 394: Twist Bioscience Corporation: Net Revenue (by Region), $Million, 2020-2022; Figure 395: Twist Bioscience Corporation: R&D Expenditure, $Million, 2020-2022; Figure 396: Revvity, Inc.: Overall Product Portfolio; Figure 397: Revvity, Inc.: Overall Financials, $Million, 2020-2022; Figure 398: Revvity, Inc.: Segment Revenue, $Million, 2020-2022; Figure 399: Revvity, Inc.: Net Revenue (by Region), $Million, 2020-2022; Figure 400: Revvity, Inc.: R&D Expenditure, $Million, 2020-2022; Figure 401: Centogene N.V.: Overall Product Portfolio; Figure 402: Centogene N.V.: Overall Financials, $Million, 2021-2022; Figure 403: Centogene N.V.: Segment Revenue, $Million, 2021-2022; Figure 404: Centogene N.V.: Net Revenue (by Region), $Million, 2021-2022; Figure 405: Centogene N.V.: R&D Expenditure, $Million, 2021-2022; Figure 406: Element Biosciences: Overall Product Portfolio; Figure 407: Ultima Genomics: Overall Product Portfolio; Figure 408: Genes2me: Overall Product Portfolio; Figure 409: LifeStrands Genomics Pte. Ltd.: Overall Product Portfolio; Figure 410: Alithea Genomics: Overall Product Portfolio; Figure 411: Real Seq Biosciences: Overall Product Portfolio
List of Tables: Table 1: Key Questions Answered in the Report; Table 2: Key Features of Short-Read vs. Long-Read Sequencing; Table 3: Comparison of Key NGS Technologies; Table 4: Some Approved NGS Panels for IVD Use; Table 5: Listed Prices of Key NGS Platforms; Table 6: Clinical NGS-Based Assays for Oncology Offerings by Companies; Table 7: Genome Sequencing Projects in Latin America and the Middle East; Table 8: Status of NGS Reimbursement in Europe; Table 9: Few of the Multi-Gene NGS Panels Available in the Market; Table 10: Key Brands of NGS Library Preparation Kits; Table 11: Strengths and Limitations of Sequencing by Synthesis (SBS); Table 12: Strengths and Limitations of Ion Torrent Semiconductor Sequencing; Table 13: Strengths and Limitations of SMRT Sequencing; Table 14: Strengths and Limitations of Nanopore Sequencing; Table 15: Strengths and Limitations of Whole Genome Sequencing; Table 16: Strengths and Limitations of Whole Exome Sequencing; Table 17: Strengths and Limitations of Targeted Sequencing; Table 18: Legal Requirements and Framework in North America; Table 19: North America NGS Market, Impact Analysis; Table 20: Genome Projects (by Country); Table 21: Legal Requirements and Framework in Europe; Table 22: Europe NGS Market, Impact Analysis; Table 23: Some of the Key Distributors in Europe (by Company); Table 24: Genome Projects (by Country); Table 25: Legal Requirements and Framework in Asia-Pacific (by Country); Table 26: Asia-Pacific NGS Market, Impact Analysis; Table 27: Some of the Key Distributors in Asia-Pacific (by Company); Table 28: Genome Projects (by Country); Table 29: Legal Requirements and Framework in the Middle East (by Country); Table 30: Middle East NGS Market, Impact Analysis; Table 31: Some of the Key Distributors in the Middle East (by Company); Table 32: Genome Projects (by Country); Table 33: Legal Requirements and Framework in Rest-of-the-World; Table 34: Rest-of-the-World NGS Market, Impact Analysis; Table 35: Genome Projects (by Country)

Pricing

Currency Rates

Single User Email from Publisher $2,750
Global Site License Email from Publisher $4,250

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now